OncoMatch

OncoMatch/Clinical Trials/NCT07736495

Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis

Is NCT07736495 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2/3 trial studies alpha lipoic acid 600 mg twice daily for colorectal cancer.

Phase 2/3RecruitingAin Shams UniversityNCT07736495Data as of Sep 2026Location: Egypt

Treatment: alpha lipoic acid 600 mg twice dailyColorectal cancer (CRC) represents one of the most common cancers worldwide and 5-Fluorouracil (5-FU) is still the mainstay of treatment. However, 5-FU is often implicated in inducing oral mucositis (OM), a painful inflammatory condition that may hinder oral intake, negatively impact quality of life and disrupt adherence with cancer treatment. Oxidative stress and inflammation play a vital role in OM pathogenesis. Alpha-lipoic acid (ALA) is a powerful antioxidant and anti-inflammatory agent that has demonstrated protective effects towards chemotherapy-induced mucosal damage in preclinical studies. Therefore, ALA may be a promising strategy to minimize or avoid 5-FU-induced oral mucositis in patients with colorectal cancer, which deserves additional clinical investigation.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

alpha lipoic acid 600 mg twice daily

Cancer type

Colorectal Cancer

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Lab requirements

Blood counts

wbcs count > 3000 cells/mm3, anc count >1500 cells/mm3 and platelets count > 100,000 cells/mm3

Kidney function

estimated glomerular filtration rate >60 ml/min

Liver function

liver transaminases level < 3 times upper normal limits and total bilirubin < 1.5 times upper normal limits

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07736495 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify